Hello??!! This drug just failed a Phase I trial, so what makes you think it will do any better for something it is LESS suited for. Drug candidates dug up from the graveyard are cheap to trial, but rarely have a pulse.
NDL is way too expensive right now. My valuation model suggests fair value at 10 - 12 cents.